Pneumococcal conjugate vaccine failure in children: A systematic review of the literature

Vaccine

Volumn 34, Issue 50, 2016, Pages 6126-6132

  Oligbu, Godwin ^a   Hsia, Yingfen ^a   Folgori, Laura ^a   Collins, Sarah ^b   Ladhani, Shamez ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Immunisation Hepatitis and Blood Safety Department Public Health England   (United Kingdom)

Author keywords

Children; Conjugate pneumococcal vaccine; Pneumococcal invasive disease; Systematic review; Vaccine failure

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

CASE CONTROL STUDY; CASE FATALITY RATE; CASE STUDY; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COCHRANE LIBRARY; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DRUG EFFICACY; EMBASE; HUMAN; IMMUNIZATION; MEDLINE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTYPE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINE FAILURE; IMMUNOLOGY; INCIDENCE; INFANT; PNEUMOCOCCAL INFECTION; TREATMENT FAILURE;

HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INCIDENCE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TREATMENT FAILURE; VACCINES, CONJUGATE;

EID: 84998772063     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.10.050     Document Type: Review

References (35)

1. [1] Conklin, L., Loo, J.D., Kirk, J., Fleming-Dutra, K.E., Deloria Knoll, M., Park, D.E., et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33:Suppl. 2 (2014), S109–S118.
2. [2] Heath, P.T., Booy, R., Griffiths, H., Clutterbuck, E., Azzopardi, H.J., Slack, M.P., et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 31:4 (2000), 973–980.
3. [3] Auckland, C., Gray, S., Borrow, R., Andrews, N., Goldblatt, D., Ramsay, M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194:12 (2006), 1745–1752.
4. [4] Braido, F., Bellotti, M., De Maria, A., Cazzola, M., Canonica, G.W., The role of Pneumococcal vaccine. Pulm Pharmacol Ther 21:4 (2008), 608–615.
5. [5] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
6. [6] Godot, C., Levy, C., Varon, E., Picard, C., Madhi, F., Cohen, R., Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Children in France. Pediatr Infect Dis J 34:10 (2015), e260–e263.
7. [7] Hsu, K., Pelton, S., Karumuri, S., Heisey-Grove, D., Klein, J., Massachusetts Department of Public Health E. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 24:1 (2005), 17–23.
8. [8] Calbo, E., Diaz, A., Canadell, E., Fabrega, J., Uriz, S., Xercavins, M., et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 12:9 (2006), 867–872.
9. [9] Whitney, C.G., Pilishvili, T., Farley, M.M., Schaffner, W., Craig, A.S., Lynfield, R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:9546 (2006), 1495–1502.
10. [10] Black, S., France, E.K., Isaacman, D., Bracken, L., Lewis, E., Hansen, J., et al. Surveillance for invasive pneumococcal disease during 2000–2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26:9 (2007), 771–777.
11. [11] Park, S.Y., Van Beneden, C.A., Pilishvili, T., Martin, M., Facklam, R.R., Whitney, C.G., et al. Invasive pneumococcal infections among vaccinated children in the United States. J Pediatr 156:3 (2010), 478–483 e472.
12. [12] Ruckinger, S., van der Linden, M., Reinert, R.R., von Kries, R., Burckhardt, F., Siedler, A., Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:31 (2009), 4136–4141.
13. [13] Bettinger, J.A., Scheifele, D.W., Kellner, J.D., Halperin, S.A., Vaudry, W., Law, B., et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine 28:9 (2010), 2130–2136.
14. [14] De Wals, P., Lefebvre, B., Defay, F., Deceuninck, G., Boulianne, N., Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 30:45 (2012), 6416–6420.
15. [15] Hanquet, G., Lernout, T., Vergison, A., Verhaegen, J., Kissling, E., Tuerlinckx, D., et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 29:16 (2011), 2856–2864.
16. [16] Martinelli, D., Pedalino, B., Cappelli, M.G., Caputi, G., Sallustio, A., Fortunato, F., et al. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010–2013. Hum. Vaccin. Immunother. 10:1 (2014), 33–39.
17. [17] Ladhani, S.N., Slack, M.P., Andrews, N.J., Waight, P.A., Borrow, R., Miller, E., Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 19:1 (2013), 61–68.
18. [18] Harboe, Z.B., Valentiner-Branth, P., Ingels, H., Rasmussen, J.N., Andersen, P.H., Bjerre, C.C., et al. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS ONE, 8(1), 2013, e51460.
19. [19] Jokinen, J., Rinta-Kokko, H., Siira, L., Palmu, A.A., Virtanen, M.J., Nohynek, H., et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children – a population-based study. PLoS ONE, 10(3), 2015, e0120290.
20. [20] Harboe, Z.B., Dalby, T., Weinberger, D.M., Benfield, T., Molbak, K., Slotved, H.C., et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 59:8 (2014), 1066–1073.
21. [21] Steens, A., Bergsaker, M.A., Aaberge, I.S., Ronning, K., Vestrheim, D.F., Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31:52 (2013), 6232–6238.
22. [22] Lehmann, D., Willis, J., Moore, H.C., Giele, C., Murphy, D., Keil, A.D., et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 50:11 (2010), 1477–1486.
23. [23] Hanna, J.N., Humphreys, J.L., Murphy, D.M., Smith, H.V., Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001–2009. Med J Aust 193:7 (2010), 392–396.
24. [24] Kellner, J.D., Vanderkooi, O.G., MacDonald, J., Church, D.L., Tyrrell, G.J., Scheifele, D.W., Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49:2 (2009), 205–212.
25. [25] Deceuninck, G., De Wals, P., Boulianne, N., De Serres, G., Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 29:6 (2010), 546–549.
26. [26] Moraga-Llop, F., Garcia-Garcia, J.J., Diaz-Conradi, A., Ciruela, P., Martinez-Osorio, J., Gonzalez-Peris, S., et al. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in catalonia, a region with low vaccination coverage. Pediatr Infect Dis J 35:4 (2016), 460–463.
27. [27] Miller, E., Andrews, N.J., Waight, P.A., Slack, M.P., George, R.C., Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11:10 (2011), 760–768.
28. [28] Alsina, L., Basteiro, M.G., de Paz, H.D., Inigo, M., de Sevilla, M.F., Trivino, M., et al. Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics. PLoS ONE, 10(3), 2015, e0118848.
29. [29] Ingels, H., Lambertsen, L., Harboe, Z.B., Marquart, H.V., Konradsen, H., Christensen, J.J., et al. Recurrent invasive pneumococcal disease in children: epidemiological, microbiological, and clinical aspects from a Danish 33-year nationwide survey (1980–2013). Scand J Infect Dis 46:4 (2014), 265–271.
30. [30] Sanz, J.C., Rodriguez-Avial, I., Rios, E., Ramos, B., Cercenado, E., Recurrent pneumococcal invasive disease in the region of Madrid during a five-year period. Infection 42:3 (2014), 475–483.
31. [31] Mason, E.O. Jr, Wald, E.R., Tan, T.Q., Schutze, G.E., Bradley, J.S., Barson, W.J., et al. Recurrent systemic pneumococcal disease in children. Pediatr Infect Dis J 26:6 (2007), 480–484.
32. [32] Ingels, H., Schejbel, L., Lundstedt, A.C., Jensen, L., Laursen, I.A., Ryder, L.P., et al. Immunodeficiency among children with recurrent invasive pneumococcal disease. Pediatr Infect Dis J 34:6 (2015), 644–651.
33. [33] Gaschignard, J., Levy, C., Chrabieh, M., Boisson, B., Bost-Bru, C., Dauger, S., et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis 59:2 (2014), 244–251.
34. [34] Turvey, S.E., Speert, D.P., Recurrent systemic pneumococcal disease and IRAK4 deficiency. Pediatr Infect Dis J, 26(11), 2007, 1074 author reply 1074.
35. [35] Pilishvili, T., Lexau, C., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201:1 (2010), 32–41.